Genetic depletion or pharmacologic inhibition of SKP2 can block the pRB deficient tumorigenesis by inducing apoptosis or suppress cancer progression by triggering p53-independent senescence in prostates of Arf−/− mice and PTEN deficient mice [2, 12, 14, 15, 37]. The gene discussed is CDKN2A; the disease is cancer.